Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

736
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
736
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

704
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
704
Varicose Veins II: Diagnostic Studies and Interprofessional Care01:26

Varicose Veins II: Diagnostic Studies and Interprofessional Care

318
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
318
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

Nature reviews. Clinical oncology·2026
Same author

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).

Future oncology (London, England)·2026
Same author

Challenges in the measurement and valuation of oncological treatments in Spain: recommendations and call to action.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Bone mineral density does not predict overall survival in patients with advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial.

Digestive diseases (Basel, Switzerland)·2026
Same author

A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).

Future oncology (London, England)·2026
Same author

A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells.

JHEP reports : innovation in hepatology·2026
Same journal

Hepatosystemic T cell licensing in MASLD-associated neuroinflammation.

Seminars in liver disease·2026
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
See all related articles

Related Experiment Video

Updated: Apr 21, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.5K

Transarterial chemoembolization and radioembolization.

Bruno Sangro1, Riad Salem2

  • 1Liver Unit, Clinica Universidad de Navarra and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Pamplona, Spain.

Seminars in Liver Disease
|November 5, 2014
PubMed
Summary
This summary is machine-generated.

Transarterial chemoembolization (TACE) and radioembolization (RE) offer non-curative treatments for liver cancer. While conventional TACE is standard for intermediate stages, RE suits advanced or TACE-refractory cases, suggesting complementary roles.

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

12.3K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.7K

Related Experiment Videos

Last Updated: Apr 21, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.5K
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

12.3K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.7K

Area of Science:

  • Interventional Radiology
  • Hepatobiliary Oncology
  • Medical Physics

Background:

  • Hepatocellular carcinoma (HCC) often requires non-curative treatments when curative options are unavailable.
  • Transarterial chemoembolization (TACE) and radioembolization (RE) are key loco-regional therapies for advanced HCC.
  • Understanding the distinct roles and potential synergy of TACE and RE is crucial for optimal patient management.

Purpose of the Study:

  • To delineate the current clinical applications and evidence base for TACE and RE in hepatocellular carcinoma.
  • To compare the indications and outcomes of conventional TACE, drug-eluting bead TACE, and RE.
  • To explore the complementary nature of TACE and RE in the treatment algorithm for HCC.

Main Methods:

  • Review of clinical trials and meta-analyses supporting conventional TACE for intermediate-stage HCC.
  • Analysis of large-cohort studies evaluating RE for advanced or TACE-refractory HCC.
  • Synthesis of evidence regarding drug-eluting bead TACE as a standardized TACE approach.

Main Results:

  • Conventional TACE is the standard of care for intermediate-stage HCC based on robust clinical trial data.
  • Drug-eluting bead TACE offers a standardized alternative with comparable outcomes and reduced systemic effects.
  • RE demonstrates efficacy in advanced HCC and in cases refractory to TACE, supported by extensive cohort data.

Conclusions:

  • TACE and RE are not competing but complementary therapies for HCC.
  • Current evidence supports TACE for intermediate stages and RE for advanced or TACE-failure scenarios.
  • Further research and ongoing studies will refine the precise indications for both TACE and RE in HCC management.